Literature DB >> 23412134

Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.

Ing-Tsung Hsiao1, Chin-Chang Huang, Chia-Ju Hsieh, Shiaw-Pyng Wey, Mei-Ping Kung, Tzu-Chen Yen, Kun-Ju Lin.   

Abstract

PURPOSE: Amyloid positron emission tomography (PET) is an important noninvasive method for detecting amyloid burden in Alzheimer's disease (AD) patients. As amyloid PET images have limited anatomical information, magnetic resonance (MR) imaging is usually acquired to perform reliable spatial normalization needed for large-scale analysis. This work proposed and evaluated the performance of new MR-free spatial normalization methods using a perfusion-like template for amyloid PET imaging.
METHODS: Amyloid PET and MR images were collected in 35 subjects (cohort 1: 8 AD patients and 6 controls; cohort 2: 15 AD patients and 6 controls). Three ligand-related templates (AD, control, mixed group) and a perfusion-like template (pAV-45) from early time frames of amyloid PET images were constructed from cohort 1. The variations of (18)F-AV-45 standardized uptake value ratios (SUVRs) among AD patients, controls, and all subjects were tested with repeated two-way (template × brain region) analysis of variance (ANOVA) in cohort 2. (18)F-AV-45 SUVRs by region of interest analysis and voxelwise analysis between MR-based and MR-free approaches were compared and correlated to clinical and image parameters. Effect size (group mean SUVR difference between AD and control/standard deviation) was also evaluated for each template method.
RESULTS: Significantly different (18)F-AV-45 SUVRs between MR-free spatial normalization and MR-based reference images were found among AD patients, controls, and all subjects by the effect of template and brain regions. The highest correlation (r=0.991) of (18)F-AV-45 SUVR to MR-based reference was found in the pAV-45 group. The SUVR percentage difference to MR-based reference showed the least variation and bias (control: -1.31±3.47 %; AD: -0.36±2.50 %) in the pAV-45 group as well. The voxelwise analysis showed the smallest t statistic value in pAV-45 followed by mixed, control, and AD groups when compared to MR-based reference images. Moreover, an overall larger effect size but compatible to that of MR-based reference result was observed in the pAV-45 group as compared to those of the other MR-free template.
CONCLUSION: The novel MR-free template based on the early-phase perfusion images pAV-45 approach for amyloid imaging showed significantly better performance in quantitation accuracy, effect size, and stability when compared with other MR-free PET templates and thus has potential for large-scale clinical applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23412134     DOI: 10.1007/s00259-013-2350-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data.

Authors:  Andrei G Vlassenko; Mark A Mintun; Chengjie Xiong; Yvette I Sheline; Alison M Goate; Tammie L S Benzinger; John C Morris
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

Review 2.  Amyloid plaque imaging from IMPY/SPECT to AV-45/PET.

Authors:  Mei-Ping Kung; Chi-Chang Weng; Kun-Ju Lin; Ing-Tsung Hsiao; Tzu-Chen Yen; Shiaw-Pyng Wey
Journal:  Chang Gung Med J       Date:  2012 May-Jun

3.  Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

Authors:  A Lobo; L J Launer; L Fratiglioni; K Andersen; A Di Carlo; M M Breteler; J R Copeland; J F Dartigues; C Jagger; J Martinez-Lage; H Soininen; A Hofman
Journal:  Neurology       Date:  2000       Impact factor: 9.910

4.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

Review 5.  Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.

Authors:  D P Rice; H M Fillit; W Max; D S Knopman; J R Lloyd; S Duttagupta
Journal:  Am J Manag Care       Date:  2001-08       Impact factor: 2.229

6.  Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.

Authors:  Philipp T Meyer; Sabine Hellwig; Florian Amtage; Christof Rottenburger; Ursula Sahm; Peter Reuland; Wolfgang A Weber; Michael Hüll
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

7.  GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.

Authors:  Cheng-Hsiang Yao; Kun-Ju Lin; Chi-Chang Weng; Ing-Tsung Hsiao; Yi-Shu Ting; Tzu-Chen Yen; Tong-Rong Jan; Daniel Skovronsky; Mei-Ping Kung; Shiaw-Pyng Wey
Journal:  Appl Radiat Isot       Date:  2010-07-07       Impact factor: 1.513

8.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

9.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

10.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.

Authors:  Nicolaas P L G Verhoeff; Alan A Wilson; Shinichiro Takeshita; Liat Trop; Doug Hussey; Kernjit Singh; Hank F Kung; Mei-Ping Kung; Sylvain Houle
Journal:  Am J Geriatr Psychiatry       Date:  2004 Nov-Dec       Impact factor: 4.105

View more
  20 in total

1.  A Fully Automatic Technique for Precise Localization and Quantification of Amyloid-β PET Scans.

Authors:  Mouna Tahmi; Wassim Bou-Zeid; Qolamreza R Razlighi
Journal:  J Nucl Med       Date:  2019-06-06       Impact factor: 10.057

2.  A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5.

Authors:  Geoffrey Warnock; Michael Sommerauer; Linjing Mu; Gloria Pla Gonzalez; Susanne Geistlich; Valerie Treyer; Roger Schibli; Alfred Buck; Stefanie D Krämer; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-27       Impact factor: 9.236

Review 3.  Spatial normalization and quantification approaches of PET imaging for neurological disorders.

Authors:  Teng Zhang; Shuang Wu; Xiaohui Zhang; Yiwu Dai; Anxin Wang; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-28       Impact factor: 10.057

4.  Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology.

Authors:  Kuan-Yi Wu; Kun-Ju Lin; Chia-Hsiang Chen; Chia-Yih Liu; Yi-Ming Wu; Cheng-Sheng Chen; Tzu-Chen Yen; Ing-Tsung Hsiao
Journal:  Front Aging Neurosci       Date:  2022-05-26       Impact factor: 5.702

5.  Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.

Authors:  Kuan-Yi Wu; Chia-Yih Liu; Cheng-Sheng Chen; Chia-Hsiang Chen; Ing-Tsung Hsiao; Chia-Ju Hsieh; Chin-Pang Lee; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

6.  Parametric estimation of reference signal intensity in the quantification of amyloid-beta deposition: an 18F-AV-45 study.

Authors:  Min Wang; Zhuangzhi Yan; Huiwei Zhang; Jiaying Lu; Ling Li; Jintai Yu; Jian Wang; Hiroshi Matsuda; Chuantao Zuo; Jiehui Jiang
Journal:  Quant Imaging Med Surg       Date:  2021-01

7.  Spatial Normalization Using Early-Phase [18F]FP-CIT PET for Quantification of Striatal Dopamine Transporter Binding.

Authors:  Sungwoo Bae; Hongyoon Choi; Wonseok Whi; Jin Chul Paeng; Gi Jeong Cheon; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-10-13

8.  Comparison of PET template-based and MRI-based image processing in the quantitative analysis of C11-raclopride PET.

Authors:  Felix P Kuhn; Geoffrey I Warnock; Cyrill Burger; Katharina Ledermann; Chantal Martin-Soelch; Alfred Buck
Journal:  EJNMMI Res       Date:  2014-01-22       Impact factor: 3.138

9.  Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases.

Authors:  Sonja Daerr; Matthias Brendel; Christian Zach; Erik Mille; Dorothee Schilling; Mathias Johannes Zacherl; Katharina Bürger; Adrian Danek; Oliver Pogarell; Andreas Schildan; Marianne Patt; Henryk Barthel; Osama Sabri; Peter Bartenstein; Axel Rominger
Journal:  Neuroimage Clin       Date:  2016-10-08       Impact factor: 4.881

10.  Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder.

Authors:  Kuan-Yi Wu; Ing-Tsung Hsiao; Chia-Hsiang Chen; Chia-Yih Liu; Jung-Lung Hsu; Sheng-Yao Huang; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.